If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

October 2, 2006 | A version of this story appeared in Volume 84, Issue 40

Air Products & Chemicals will build a liquid-nitrogen plant for NASA's National Transonic Facility, a cryogenic wind tunnel at the Langley Research Center in Hampton, Va. The contract has a maximum value of $16 million.

Kyowa Hakko will begin commercial production in Japan next year of l-tyrosine using a new fermentation process. The amino acid, reputed to have stress-relieving effects, is traditionally made from animal hair or feathers.

Omnova Solutions will sell its GenFlex building products division, serving the single-ply roofing market, to Firestone Building Products, which is part of Bridgestone's American operations. Omnova expects to realize about $40 million from the sale.

Cabot says it will cut 130 jobs and take a charge of $15 million before taxes to reduce the cost structure of its carbon black product lines. Most of the charge will be for one-time employment termination benefits, the firm says.

GenTek has agreed to acquire the assets of GAC MidAmerica for $7.8 million before any working capital adjustment. Toledo, Ohio-based GAC produces aluminum sulfate and bleach, and distributes sulfuric acid, caustic soda, and water treatment chemicals.

Sareum will use its protein-structure determination capabilities to accelerate Roche's cancer drug discovery research. The England-based firm says it can help illustrate how Roche's drug candidates interact with target receptor proteins.

ChemBridge Corp. and ChemBridge Research Laboratories have signed a multiyear discovery chemistry pact with AstraZeneca. ChemBridge scientists in Moscow and San Diego will develop small-molecule libraries to enhance AstraZeneca's drug discovery effort.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.